NCT04737928CompletedNot Applicable
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders
Santen Pharmaceutical (Taiwan) Co., LTD1 site in 1 country1 target enrollmentStarted: April 2, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Safety:Changes in the fluorescein staining score (NEI) at Visit 2
Study Overview
Brief Summary
The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a time, once daily) to the 0.0015% tafluprost ophthalmic solution (one drop at a time, once daily). Efficacy also was investigated.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age of 20 years or older and those who was provided informed consent.
- •POAG or OH patients whose IOP did not exceed 22 mmHg at Visit
- •Patients had treated with prostaglandin ophthalmic solution (0.005% Latanoprost) for at least 3 months before enrollment.
- •Patients who had corneal disorders due to the PG usage. (At least one eye had a score above 1 on the NEI scale)
- •If only one eye was eligible, it was evaluated. When both eyes were eligible, then the eye with a higher NEI score was selected for evaluation.
- •Outpatients who visited the clinic on the designated day as instructed by the physician.
Exclusion Criteria
- •Those with severe visual field disorder (Mean deviation of 15 dB or worse).
- •Those who received corneal refractive surgery.
- •Those with a history of ocular surgeries (such as corneal refractive surgery, intraocular surgery including ocular laser treatment which affected the patient's ocular surface condition) within 3 months prior to enrollment.
- •Any corneal abnormality or other condition preventing IOP measurement.
- •Those who used artificial tears to relieve dry eye symptoms.
- •Those with severe dry eye, ocular allergy, ocular infection or ocular inflammation which considered affect interpretation of the results of the study. Those who used systemic or ophthalmic steroids (excluding topical skin steroidal ointment) and anti-glaucoma agents other than prostaglandin ophthalmic solution.
- •Female patients who were pregnant, nursing or lactating.
- •Those with a history of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the study medication.
- •Those who wore contact lenses during the study period.
- •Those who had participation in another clinical trial involving an investigational drug/device, or participation in such a trial within the last 30 days.
Arms & Interventions
latanoprost switch to tafluprost
Experimental
POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
Intervention: Latanoprost (Drug)
latanoprost switch to tafluprost
Experimental
POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
Intervention: tafluprost (Drug)
Outcomes
Primary Outcomes
Safety:Changes in the fluorescein staining score (NEI) at Visit 2
Time Frame: 3 months
fluorescein staining
Efficacy: Changes in the Intraocular Pressure (IOP) at each visit
Time Frame: 3 months
Tonometer
Secondary Outcomes
- Concomitant medication(3 months)
- Changes in the fluorescein staining score (NEI) at Visit 1(1 months)
- Changes in ocular symptoms (irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation) at each visit(3 months)
- Changes in the Tear Break-Up Time (TBUT) at each visit(3 months)
- Changes in the hyperaemia at each visit(3 months)
- Treatment compliance(3 months)
- Patient satisfaction about test medication(3 months)
- Usability of eyedrop bottle(3 months)
- Adverse drug reactions(3 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Ocular Surface Disease Changes After iStent or iStent Inject Implantation With PhacoemulsificationOcular Surface DiseaseGlaucoma, Open-AngleNCT04452279Vance Thompson Vision47
Completed
Not Applicable
Perceptual Learning Improve Visual Function in Patients With KeratoconusKeratoconus, StableNCT05220904Zhongshan Ophthalmic Center, Sun Yat-sen University35
Completed
Not Applicable
Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue SoftwareGlaucomaCataractNCT04486976Tomey Corporation134
Completed
Not Applicable
Comparison of Femto-laser and Manually Created Clear Corneal Incisions During Cataract SurgeryCataractNCT04082273Ziemer Ophthalmic Systems AG80
Withdrawn
Phase 2
OSIG-eye Drops Treatment for Dry Eye DiseaseDry EyeNCT04510428University of Illinois at Chicago